Status and phase
Conditions
Treatments
About
This phase Ⅱ study was designed to evaluate the efficacy and safety of mFOLFIRINOX as first-line treatment for metastatic pancreatic cancer in China.
Full description
Although FOLFIRINOX regimen was recently presented to be effective for metastatic pancreatic cancer in selected patients who have good physical condition, there is still insufficient evidence on this regimen in treating patients with metastatic pancreatic cancer in China. Since for many tumors, different races may show different responses to the same regimen, we design this open, multicenter phase Ⅱ study to evaluate the the efficacy and safety of mFOLFIRINOX as first-line treatment for metastatic pancreatic cancer in China.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients have provided a signed Informed Consent Form
ECOG performance status of 0-1
BMI ≥ 18.5
Age: 18-65 years old
Histologically confirmed diagnosis of metastatic pancreatic cancer
No prior palliative chemotherapy
Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria
Life expectancy ≥ 3 months
Patient has adequate bone marrow and organ function
Patient has adequate liver function
Creatinine ≤ 1.25 times ULN
Good compliance
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal